October 3, 2022
A BIG week of economic data and a cautious tred for share pricing
News: REGENXBIO (RGNX) announced positive interim data from the P2 AAVIATE® trial of RGX-314 for the treatment of wet AMD using suprachoroidal delivery. REGENXBIO also presented positive interim data from the P1/2a long-term follow-up (LTFU) study of RGX-314 for the treatment of wet AMD using subretinal delivery at the American Academy of Ophthalmology (AAO) annual meeting this past weekend in Chicago.
Indications: 1 Negative Indications, 2 New BUY Favorite, 5 Positive Indication with 1 Pump/Promote (BSTG – the usual suspect)
No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes
Why do I keep writing this blog/newsletter to inform investors, what they need to hear that others won’t say or write!
8:00 a.m. edition
September 30, 2022
Solid Biosciences (SLDB a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne) and Aavanti Bio, Inc., a privately-held gene therapy company focused on transforming the lives of patients with Friedreich’s ataxia and rare cardiomyopathies, today announced that the companies have entered into a definitive merger agreement including its pipeline assets and net cash.
SLDB will acquire AavantiBio, including its pipeline assets and net cash.
The combined company will focus on advancing a portfolio of neuromuscular and cardiac programs, led by SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne. Additional pipeline programs include AVB-202, a gene transfer candidate for the treatment of Friedreich’s ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases.
September 30, 2022
NO positive catalysts drove up the cell and gene therapy equities through the end of the Friday session
Pre-open indications: 2 HITs, 1 MISS and 1 BUY Bottom – Agenus (AGEN)
WHY and HOW is this market affecting the cell and gene therapy sector … “The Bottom Line” underlines the framework of share pricing actions.
No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes.
Why do I keep writing this blog/newsletter; to inform investors, what others won’t say or write!
The week in review as the month and Q3 ends
September 30, 2022
Solid Biosciences (SLDB a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne) and Aavanti Bio, Inc., a privately-held gene therapy company focused on transforming the lives of patients with Friedreich’s ataxia and rare cardiomyopathies, today announced that the companies have entered into a definitive merger agreement including its pipeline assets and net cash. SLDB will acquire AavantiBio, including its pipeline assets and net cash. The combined company will focus on advancing a portfolio of neuromuscular and cardiac programs, led by SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne. Additional pipeline programs include AVB-202, a gene transfer candidate for the treatment of Friedreich’s ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases.
September 28, 2022
Trying to HIDE end-of-year Annual Report (10-K) status and an S-8 registration Statement for proposed offering? Still has a “going concern” status, considered good for the time being? It means its business is facing financial distress but is still able to make payments to keep it operating at least the next 12 months. Recurring losses, accumulated deficit of $308.2 million and a fading share pricing at $0.30 with a 52-week change of -90.87% (low of $0.28 and a high of $3.295)
September 21, 2022
A second approval ... Also the largest volume of three (3) session: bluebird bio (BLUE) +9.118 million shares traded (-$0.69) after Tuesday’s +21.503 million shares traded (+$0.93) after Monday’s -30.962 million share traded (-$0.41 or -6.47%) – EXPECT an offering! BLUE also confirmed that the previous clinical hold on the eli-cel clinical development program has been lifted. Therapy pricing is an issue...
4 hours 50 min ago
RegMed Investors’ (RMi) pre-open: Q4 kicks off
© 2022 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
